Tags: Drug.

Darapladib is a drug used to inhibit lipoprotein-associated phospholipase A2 (Lp-PLA2) and is being investigated as a possible add-on treatment for atherosclerosis.On Tuesday November 12 2013 GlaxoSmithKline announced that the drug had failed to meet Phase III endpoints in a trial of 16000 patients with acute coronary syndrome. An additional trial of 13000 patients (SOLID-TIMI 52) is ongoing.

Darapladib_structure.svg
ATC prefix
none
CAS number
356057-34-6
FDA UNII code
UI1U1MYH09
IUPAC name
N-(2-diethylaminoethyl)-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-67-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
PubChem
9939609

Loading...

This page contains content from the copyrighted Wikipedia article "Darapladib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.